Celldex Therapeutics Inc.

10/26/2024 | Press release | Distributed by Public on 10/26/2024 18:31

Celldex Announces Barzolvolimab Met All Primary and Secondary Endpoints with High Statistical Significance in Positive Phase 2 Study in Chronic Inducible Urticaria

Read this content
Click here to read the original version at the source's official website. The text of this article is not available at the moment.